Every material Form 8-K CalciMedica, Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CalciMedica's Chief Financial Officer, principal accounting officer and principal financial officer, Stephen Bardin, gave notice of his resignation on October 15, 2026, to pursue another professional opportunity. The resignation takes effect immediately after the company files its Form 10-Q for the quarter ended September 30, 2026, and the company said it was not due to any disagreement.
Stephen Bardin is CFO, principal accounting officer and principal financial officer.
Notice given October 15, 2026; effective immediately after the Q3 2026 Form 10-Q is filed.
Resignation is to pursue another professional opportunity, and the company states no disagreement was involved.
The filing names no successor or interim financial officer.
CalciMedica filed a prospectus supplement covering the sale of up to $25,000,000 of its common stock through an at-the-market offering agreement with H.C. Wainwright & Co. The filing sets up a possible share sale program but does not state that any shares have been sold or at what price. Because new shares could dilute existing holders, the filing is relevant to shareholders.
Up to $25,000,000 of common stock may be sold under the at-the-market offering agreement dated August 11, 2023
Sales are made under shelf registration Form S-3 (No. 333-293972), filed March 3, 2026 and declared effective March 11, 2026
Cooley LLP legal opinion on the legality of the shares is filed as Exhibit 5.1
CalciMedica received a Nasdaq letter on September 15, 2026 confirming it has regained compliance with the minimum bid price rule, after its closing bid stayed at $1.00 or greater for 10 consecutive business days from August 31 to September 14, 2026. The company has no outstanding Nasdaq deficiency notices, which removes the risk of delisting over the bid price issue for shareholders.
Nasdaq notice of non-compliance dated March 16, 2026, after the bid price was below $1.00 for 30 consecutive business days
Compliance deadline was September 14, 2026, 180 calendar days after the notice
Nasdaq letter received September 15, 2026 confirmed compliance with Listing Rule 5550(a)(2)
Company reports no outstanding Nasdaq deficiency notices as of the filing date
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CalciMedica, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →